drugset
drugset / Trial / NCT04605562

Umbrella Biomarker-Guided Therapy in NPC

NCT04605562 ↗

Phase 2 Not yet recruiting 206 enrolled Sun Yat-sen University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted treatment in high-risk locoregionally advanced nasopharyngeal carcinoma. The specific grouping of patients' depends on the SYSUCC immune subtyping based on 100+ gene panel testing.

Timeline

Start
2022-06
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Galunisertib Small molecule — —
Subject Palbociclib Small molecule — Oral
Background Cisplatin Other / unclassified 100 mg/m2 —
Background Gemcitabine Small molecule 1000 mg/m2 —

Indications

nasopharyngeal carcinoma